Monitor for prospectus supplements that would trigger actual sales under the shelf. The company's cash runway into early 2027 makes near-term drawdowns likely. Any offering would be highly dilutive relative to the $3M market cap.
Price Chart
How similar events traded
Executive Summary
Decoy Therapeutics filed a universal shelf registration statement on Form S-3 to register up to $50 million in securities (common stock, preferred stock, warrants, debt securities, units). The filing comes one day after the company's 10-Q disclosed a going concern warning, cash runway only into early 2027, and a market cap of $3M. The shelf is a capital-raising tool for a pre-revenue biotech with urgent funding needs.
Key Financial Metrics
Key Facts
- Shelf registration of up to $50,000,000 in securities (common, preferred, warrants, debt, units).
- Market cap is approximately $3M; public float is approximately $2.5M (68,748 shares held by non-affiliates).
- Company has a going concern warning; cash expected to fund operations only into early 2027.
- 18 offering/registration filings in the last 24 months, indicating repeated capital raises.
- Nasdaq listing at risk due to potential MVLS Rule ($5M minimum market value) and existing Mandatory Panel Monitor through March 2027.
- No revenue from product sales; pre-clinical stage biotechnology company.
Financial Impact
Up to $50 million in potential dilution, which is approximately 17x current market cap of $3M. Any actual issuance would be massively dilutive.
Risk Factors
- Massive dilution risk: $50M shelf is 17x current market cap.
- Going concern risk: cash only into early 2027; company needs capital urgently.
- Nasdaq delisting risk: market cap below proposed $5M MVLS threshold; company under Mandatory Panel Monitor.
- Repeated capital raises (18 filings in 24 months) suggest structural funding dependency.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-460860 |
| Document: dcoy-ex5_1.htm | 0001193125-26-460860 |
| Document: dcoy-exfiling_fees.htm | 0001193125-26-460860 |
| Document: dcoy-ex23_1.htm | 0001193125-26-460860 |
| Document: 0001193125-26-460860-index-headers.html | 0001193125-26-460860 |
| Document: 0001193125-26-460860-index.html | 0001193125-26-460860 |
| Document: 0001193125-26-460860.txt | 0001193125-26-460860 |
Track record
13 reports on DCOY
3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +67.67% at T+60 after the Jun 29, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 13, 20263d ago S-3 Bearish 6/10 Viewing Entry $1.02 Now $0.9010 +11.66% settles Dec 15
- Nov 3, 202613d ago Press Release Neutral 3/10 Entry $1.11 Now $0.9010 −18.83% settles Dec 2
- Oct 19, 202629d ago EFFECT Neutral 4/10 Entry $1.17 to $0.9752 Now $0.9010 −22.99% ▼ −16.65% −13.19% vs SPY
- Oct 7, 20265w ago S-1 Bearish 6/10 Entry $1.52 to $1.14 Now $0.9010 +40.72% ▲ +25.00% +19.71% vs SPY
- Sep 23, 20267w ago 8-K Bearish 6/10 Entry $3.11 to $1.03 Now $0.9010 +71.03% ▲ +66.88% +66.46% vs SPY
- Aug 4, 202614w ago DEFA14A Neutral 3/10 Entry $4.19 to $2.98 Now $0.9010 −78.50% ▼ −28.88% −28.28% vs SPY
- Jul 20, 202617w ago EFFECT Neutral 4/10 Entry $5.31 to $3.52 Now $0.9010 −83.02% ▼ −33.65% −37.77% vs SPY
- Jun 29, 202620w ago 8-K Bearish 7/10 Entry $9.59 to $5.04 Now $0.9010 +90.60% ▲ +47.45% +47.17% vs SPY
- Jun 25, 202620w ago EFFECT Neutral 5/10 Entry $5.92 to $4.94 Now $0.9010 −84.78% ▼ −16.53% −17.05% vs SPY
- Jun 4, 202623w ago DEFA14A Neutral 3/10 Entry $6.71 to $7.31 Now $0.9010 −86.57% ▲ +8.94% +10.31% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers